Cancer immunotherapy targeting Wilms' tumor gene WT1 product (Q36238704)

13 August 2017

1 reference

title

Cancer immunotherapy targeting Wilms' tumor gene WT1 product. (English)

1 reference

13 August 2017

1 reference

Haruo Sugiyama

1

1 reference

13 August 2017

publication date

1 August 2005

1 reference

Expert Review of Vaccines

13 August 2017

published in

1 reference

13 August 2017

volume

4

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

503-512

1 reference

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Repression of the c-myb gene by WT1 protein in T and B cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

The role of WT1 in oncogenesis: tumor suppressor or oncogene?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Wilms' tumor gene WT1: its oncogenic function and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.503

21 January 2018

Identifiers

DOI

10.1586/14760584.4.4.503

1 reference

13 August 2017

1 reference